497 related articles for article (PubMed ID: 18303156)
1. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study.
Weigert G; Michels S; Sacu S; Varga A; Prager F; Geitzenauer W; Schmidt-Erfurth U
Br J Ophthalmol; 2008 Mar; 92(3):356-60. PubMed ID: 18303156
[TBL] [Abstract][Full Text] [Related]
2. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results.
Sacu S; Michels S; Prager F; Weigert G; Dunavoelgyi R; Geitzenauer W; Pruente C; Schmidt-Erfurth U
Eye (Lond); 2009 Dec; 23(12):2223-7. PubMed ID: 19169239
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration.
Krebs I; Lie S; Stolba U; Zeiler F; Felke S; Binder S
Acta Ophthalmol; 2009 Sep; 87(6):611-7. PubMed ID: 18937801
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
[TBL] [Abstract][Full Text] [Related]
8. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
9. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
10. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
Costagliola C; Romano MR; Rinaldi M; dell'Omo R; Chiosi F; Menzione M; Semeraro F
Br J Ophthalmol; 2010 Feb; 94(2):180-4. PubMed ID: 19965822
[TBL] [Abstract][Full Text] [Related]
11. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.
Moshfeghi AA; Rosenfeld PJ; Puliafito CA; Michels S; Marcus EN; Lenchus JD; Venkatraman AS
Ophthalmology; 2006 Nov; 113(11):2002.e1-12. PubMed ID: 17027972
[TBL] [Abstract][Full Text] [Related]
12. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study.
Potter MJ; Claudio CC; Szabo SM
Br J Ophthalmol; 2010 Feb; 94(2):174-9. PubMed ID: 19520690
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U
Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
[TBL] [Abstract][Full Text] [Related]
15. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.
Michels S; Rosenfeld PJ; Puliafito CA; Marcus EN; Venkatraman AS
Ophthalmology; 2005 Jun; 112(6):1035-47. PubMed ID: 15936441
[TBL] [Abstract][Full Text] [Related]
16. [Early effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related macular degeneration].
Geitzenauer W; Michels S; Prager F; Kornek G; Vormittag L; Rosenfeld P; Schmidt-Erfurth U
Klin Monbl Augenheilkd; 2006 Oct; 223(10):822-7. PubMed ID: 17063425
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results.
Carneiro AM; Falcão MS; Brandão EM; Falcão-Reis FM
Retina; 2010 Jan; 30(1):85-92. PubMed ID: 20010320
[TBL] [Abstract][Full Text] [Related]
18. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
19. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone.
Yip PP; Woo CF; Tang HH; Ho CK
Br J Ophthalmol; 2009 Jun; 93(6):754-8. PubMed ID: 19273471
[TBL] [Abstract][Full Text] [Related]
20. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
